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The pharmacokinetics and pharmacodynamics of any drug will depend, largely, on the interaction that it has
with human serum albumin (HSA), the most abundant plasma protein. The interaction between newly
synthesized Pd(II) complexes, 2,2′-bipyridin octyl dithiocarbamato Pd(II) nitrate (Octpd), 2,2′-bipyridin butyl
dithiocarbamato Pd(II) nitrate (ButPd), 2,2′-bipyridin ethyl dithiocarbamato Pd(II) nitrate (EtPd), antitumor
components, with human serum albumin, a carrier protein, were studied at different temperatures of 27 and
37 °C by fluorescence spectroscopy, far UV circular dichroism (CD), and spectrophotometric and differential
scanning calorimetry (DSC) techniques. By the analysis of fluorescence intensity, it was observed that Pd(II)
complexes have strong abilities to quench the intrinsic fluorescence of HSA through a dynamic quenching
procedure. The binding parameters were evaluated by the fluorescence quenching method. The thermodynamic
parameters, including ∆H°, ∆S°, and ∆G°, were calculated by the fluorescence quenching method and indicated
that hydrophobic forces play a major role in the interaction of Pd(II) complexes with HSA. Far-UV-CD
results represented that Pd(II) complexes induced a decrease in content of the R helical structure of protein.
The binding of newly designed drugs (Pd(II) complexes) on the blood carrier protein of HSA resulted in
significant alterations on the structure and conformation of protein via decreasing stability of HSA by decreasing
the Tm, a red shift in maximum fluorescence intensity, a decrease in content of the R-helical structure, and the
increase of the nonpolar or accessible hydrophobic surface of HSA to solvent.
Introduction
Human serum albumin (HSA) is the most abundant protein
constituent of blood plasma and serves as a protein storage
component. Its three-dimensional structure has been determined
through X-ray crystallographic measurements. This protein is
a single-chain 66 kDa protein, which is largely R-helical and
consists of three structurally homologous domains that assemble
to form a heart-shaped molecule.1,2 Each domain is a product
of two subdomains, which are predominantly helical and
extensively cross-linked by several disulfide bridges. Its amino
acid sequence contains a total of 17 disulfide bridges, one free
thiol (Cys 34), and a single tryptophan (Trp-214).3,4
HSA can bind and carry through the bloodstream many drugs,
which are poorly soluble in water.5,6 It has been shown that the
distribution, free concentration, and metabolism of various drugs
can be significantly altered as a result of their binding to HSA.7
Drug interactions at the protein binding level will in most cases
significantly affect the apparent distribution volume of the drugs
and also affect the elimination rate of drugs; therefore, the
studies on this aspect can provide information on the structural
features that determine the therapeutic affectivity of drugs and
have been an interesting research field in life sciences, chemistry,
and clinical medicine.8-10
The discovery of cis-platinum compounds as an antitumor
drug has prompted intensive research into the development of
compounds with lower toxicity and higher selectivity toward
the tumor cells.11 Platinum(II) complexes including cis-platin
and carboplatin are widely used in the treatment of several
human malignant diseases, such as ovarian, testicular, lung,
urinary bladder, head, and neck cancer.12,13 However, cis-platin
and its analogues produce several side effects including nephro-
toxicity, coming out in injury to renal tubular epithelial cells
and can be revealed as either acute renal failure or a chronic
syndrome characterized by renal electrolyte wasting.12,14 Several
reports have demonstrated that the binding of platinum com-
plexes to the N7-nitrogens of two adjacent guanosine bases is
thought to disrupt DNA duplication leading to cell death.
However, platinum complexes are also known to react with
many other cell components including glutathione and other
S-containing biomolecules, present in relatively high doses
inside the cell.15,16 Recent studies have shown that platinum
complexes can bind and inactivate the thiol-containing enzymes
of the renal and have serious side effects on the kidney.12,16
Because palladium chemistry is similar to that of platinum, it
was speculated that Pd complexes might also exhibit antitumor
activities with lower side effects than platinum(II) complexes.
Attempts have been made to synthesize Pd(II) complexes with
such activities. Palladium complexes are expected to have lower
kidney toxicity than cis-platin due to their inability to replace
the tightly bound chelate ligands of Pd(II) with sulfhydryl groups
of protein kidney tubules.14,17,15 Our group18 and others16,19,20
have reported that Pd(II) complexes also have significant
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